Last $5.91 USD
Change Today -0.17 / -2.80%
Volume 3.9M
MNKD On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (MNKD) Snapshot

Open
$6.09
Previous Close
$6.08
Day High
$6.12
Day Low
$5.91
52 Week High
06/30/14 - $11.48
52 Week Low
03/31/14 - $3.80
Market Cap
2.4B
Average Volume 10 Days
5.2M
EPS TTM
$-0.66
Shares Outstanding
402.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MANNKIND CORP (MNKD)

mannkind corp (MNKD) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

265 Employees
Last Reported Date: 03/3/14
Founded in 1991

mannkind corp (MNKD) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $824.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $718.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $440.8K
Chief Technical Officer and Corporate Vice Pr...
Total Annual Compensation: $459.1K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2013.

mannkind corp (MNKD) Key Developments

MannKind Closes Global Licensing Agreement with Sanofi

MannKind Corporation announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The closing follows completion of the US Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act and the completion of documentation related to the USD 175 million loan facility being provided to MannKind by an affiliate of Sanofi in connection with the collaboration and license agreement. Under the terms of the collaboration and license agreement, MannKind will receive a USD 150 million upfront payment within ten days of the closing.

MannKind Announces Closing of Global Licensing Agreement with Sanofi

MannKind Corporation announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza(R) (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The closing follows completion of the US Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act and the completion of documentation related to the $175 million loan facility being provided to MannKind by an affiliate of Sanofi in connection with the collaboration and license agreement. Under the terms of the collaboration and license agreement, MannKind will receive a $150 million upfront payment within ten days of the closing.

Sanofi and MannKind Partner to Develop and Commercialise Afrezza to Treat Diabetes

Sanofi and MannKind have signed an exclusive licensing agreement to develop and commercialise Afrezza (insulin human) inhalation powder. Afrezza is a new rapid-acting inhaled insulin therapy developed to treat adults with type I and type II diabetes. As part of the deal, both firms plan to introduce Afrezza in the US in the first quarter of 2015. Sanofi will undertake global commercial, regulatory and development activities of Afrezza, while MannKind will manufacture Afrezza at its production facility in Danbury, Connecticut, US under a separate supply agreement. The firms are also planning to collaborate to expand their manufacturing capacity to meet global demand. Based on the terms of the agreement, MannKind will receive an upfront payment of $150 million and potential milestone payments of up to $775 million. Sanofi has agreed to provide its share of the collaboration's expenses up to a limit of $175 million to MannKind.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNKD:US $5.91 USD -0.17

MNKD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNKD.
View Industry Companies
 

Industry Analysis

MNKD

Industry Average

Valuation MNKD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit www.mannkindcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.